have been reported (< 1%). KYPROLIS can cause elevations of serum transaminases and bilirubin.
Withhold KYPROLIS in patients experiencing Grade 3 or greater elevations of transaminases, bilirubin, or
other liver abnormalities until resolved or returned to baseline. After resolution, consider if restarting
KYPROLIS is appropriate. Monitor liver enzymes frequently [see Dosage and Administration and Adverse
Reactions]. Embryo-fetal Toxicity. KYPROLIS can cause fetal harm when administered to a pregnant
woman based on its mechanism of action and findings in animals. There are no adequate and well‑controlled
studies in pregnant women using KYPROLIS. Carfilzomib caused embryo‑fetal toxicity in pregnant rabbits at
d